San Diego-dependent Viking Therapeutics marked itself as a significant competitor inside the weight loss drug market place in February following revealing promising facts from the mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied as being a weekly injection and in March